1

1 An economic evaluation of two cervical screening algorithms in Belgium: HR-HPV primary compared

- 2 to HR-HPV and liquid-based cytology (LBC) co-testing
- 3 Running head:
- 4 Economic evaluation of cervical screening algorithms in Belgium

5 <u>Authors</u>

- 6 Caroline Dombrowski¹, Claire Bourgain², Yixuan Ma¹, Anne Meiwald¹, Amy Pinsent¹, Birgit Weynand²
- 7 Katy ME Turner¹, Susie Huntington¹, *Elisabeth J Adams¹, Johannes Bogers^{2, 3}, Romaric Croes⁴, Shaira
- 8 Sahebali².
- 9
- 10 <u>Author affiliations</u>
- ¹Aquarius Population Health, London, UK
- 12 ²The Cytology Working Group of the Belgian Society of Pathology, Belgium
- ³University of Antwerp, Laboratory for Cell Biology and Histology, Antwerp, Belgium
- ⁴Belgian Society of Pathology, Belgium

15

- 16 <u>*Corresponding author</u>: Dr Elisabeth Adams
- 17 Aquarius Population Health, Unit 29 Tileyard Studios, London N7 9AH, UK
- 18 Email: Elisabeth.Adams@aquariusph.com, Telephone: +44 (0) 207 993 2930
- 19
- 20 <u>Ethics statement</u>
- 21 Ethical review and approvals were not required or sought as this paper reports a theoretical health
- 22 economic evaluation of two cervical screening algorithms and patients were not involved in the
- 23 evaluation.

2

24 <u>Source of Funding and Competing Interests</u>

- 25 Aquarius Population Health received funding from Hologic for this study; the design, results and
- 26 interpretation of the study are independent and the authors' own.
- 27 At the time of writing, CD, YM, AM, AP, KT, SH and EA were all part of Aquarius Population Health Ltd, an
- 28 independent consultancy which has previously worked on projects related to diagnostic screening for
- 29 numerous commercial and non-commercial organisations.
- 30 CB, BW, JB, RC, SS have no competing interests to disclose.
- 31

32 <u>Author Contribution Statement</u>

- 33 CD: Methodology, analysis, project administration, interpretation, supervision, writing review &
- editing; CB: Writing review & editing; YM: validation, analysis, visualization, writing original draft,
- 35 AM: Conceptualization, methodology, analysis, data curation; AP: Conceptualization, methodology,
- analysis, data curation; BW: Writing review & editing; KT: Conceptualization, supervision. SH:
- 37 supervision, writing review & editing; EA: Conceptualization, supervision, writing review & editing;
- 38 JB: Writing review & editing; RC: Writing review & editing; SS Writing review & editing.
- 39 All authors reviewed and approved the final manuscript.
- 40

3

41 Abstract

Objective: To assess the costs and benefits of two algorithms for cervical cancer screening in Belgium 1)
high-risk human papillomavirus (HR-HPV) primary screening and 2) HR-HPV and liquid-based cytology
(LBC) co-testing.

45 Methods: A decision tree was adapted from published work and parameterised using HORIZON study 46 data and Belgian cost and population data. The theoretical model represents two different screening 47 algorithms for a cohort of 577,846 women aged 25 – 64 attending routine cervical screening. Scenario 48 analyses were used to explore the impact of including vaccinated women and alternative pricing 49 approaches. Uncertainty analyses were conducted. 50 **Results**: The cost per woman screened was €113.50 for HR-HPV primary screening and €101.70 for co-51 testing, representing a total cost of €65,588,573 and €58,775,083 respectively for the cohort; a 10% 52 difference. For one screening cycle, compared to HR-HPV primary, co-testing resulted in 13,173 more 53 colposcopies, 67,731 more HR-HPV tests and 477,020 more LBC tests. Co-testing identified 2,351 more 54 CIN2+ cases per year (27% more than HR-HPV primary) and 1,602 more CIN3+ cases (24% more than HR-55 HPV primary) than HR-HPV primary. 56

56 Conclusion: In Belgium, a co-testing testing algorithm could increase cervical precancer detection rates 57 compared to HR-HPV primary. Co-testing would cost less than HR-HPV primary if the cost of the HPV 58 test and LBC were cost-neutral compared to the current cost of LBC screening but would cost more if 59 the cost per HPV test and LBC were the same in both co-testing and HR-HPV primary strategies.

60 Keywords: HR-HPV infection; Cervical Cancer screening; HPV; Co-testing; Belgium; Economic Model

4

61 Introduction

62 Cervical cancer, caused by high-risk human papillomavirus (HR-HPV), is a leading cause of mortality in
63 women (WHO, 2022). While not all HR-HPV infections result in cancer, persistent HR-HPV infection can
64 lead to cervical abnormalities, which if not detected and treated, progress to invasive cervical cancer
65 (Monsonego et al., 2004).

66 The World Health Organization (WHO) has set a global target to eliminate cervical cancer through a 67 combined approach of prevention (HR-HPV vaccination), testing (cervical screening programmes) and 68 treatment (WHO, 2020a). Cervical screening can identify HR-HPV and cervical cell abnormalities that, 69 when detected at an early stage, can be managed to reduce the risk of disease progression and 70 mortality (Jansen et al., 2020). While many high-income countries have offered high-quality cervical 71 screening via Pap smear tests for many years, technological advancements in testing and interventions, 72 including HR-HPV vaccination, have led countries to review their existing programmes (Anttila et al., 73 2004). Studies demonstrated the benefits of HPV-based screening (Ronco et al., 2014) and some 74 countries have or will transition from cytology-based screening to HR-HPV primary testing with LBC 75 (liquid-based cytology) following an HR-HPV positive result (Maver and Poljak, 2020)). Other countries, 76 like the United States (US) and Germany (Fontham et al., 2020; Xhaja et al., 2022), have chosen to 77 implement co-testing (using LBC and HR-HPV testing concurrently) as studies suggest that co-testing can 78 detect more people who are HR-HPV negative but have abnormal cytology. Approximately 3-14% 79 (precancer) or 13-18% (cancer) cases are HPV negative and are therefore missed using HR-HPV primary 80 testing (Austin R.M. et al., 2018; Vasilyeva et al., 2021, Blatt et al., 2015a; Kaufman et al., 2020). F 81 Data from a large study in Belgium in 2010 indicates the prevalence of HR-HPV is around 13% in women 82 (Depuydt et al., 2010), with approximately 3,000 cases of carcinoma *in situ* (Arbyn Marc et al., 2015) 83 and 600 new cases of invasive cervical cancer diagnosed annually (Bruni et al., 2023). Although access to

© Aquarius Population Health 2023

5

84	screening is available, there is currently no centrally organised national cervical screening programme.
85	Screening coverage was reported as 61% nationally for the period 2004-2006 (Arbyn et al., 2014) and
86	more recently, as 62.6% in Flanders (Flemish Department of care, 2021). Regional health authorities are
87	responsible for screening and their approaches vary. In Flanders, women aged 25 – 64 receive an LBC
88	test every three years in a semi-organised screening programme, while in French-speaking regions,
89	screening is opportunistic (Van Kerrebroeck and Makar, 2016). In 2020, a pilot screening program for
90	women aged 25-64 launched in Wallonia. HR-HPV vaccination coverage varies considerably by region
91	from 91% in Flanders (Thiry et al., 2019) to 31-50% in French-speaking regions (Bonanni et al., 2020).
92	As the Belgium government considers moving from a regionally organised cytology-based screening to a
93	national HR-HPV primary screening programme, it is important to consider the costs and potential
94	benefits of different screening algorithms. Health economic models can be used to inform decision
95	making by quantifying the outcomes of different screening algorithms within a given setting (Mendes et
96	al., 2015). This study uses a decision tree model to assess the health and economic outcomes of a HR-
97	HPV primary screening algorithm compared to co-testing algorithm in Belgium.
98	Methods
99	Model overview
100	A decision tree model was developed in Excel v2202 (Microsoft, Redmond, WA, USA) to simulate
101	potential cervical screening algorithms for Belgium, comparing HR-HPV primary with co-testing
102	algorithms. A cost-consequence analysis was undertaken from the perspective of the Belgian healthcare
103	system.
104	Cervical screening algorithm
105	A national cervical screening algorithm for HR-HPV primary screening in Belgium has not yet been
106	finalised, therefore theoretical cervical screening algorithms were developed for the Belgium setting

6

(Figure 1); the HR-HPV primary algorithm was adapted from the Netherlands screening algorithm (RIVM,
2021) and the co-testing algorithm was adapted from screening algorithms in Germany and Luxembourg
(Iftner, 2021; Secrétariat du Conseil Scientifique, 2019).

110 In the HR-HPV primary algorithm, women have a cervical sample taken which is tested for HR-HPV

111 (Figure 1). Those who test negative return for re-testing every 5 years (hereafter referred to as the

routine screening cycle) and HR-HPV positive samples are tested using reflex-LBC Those with normal

baseline LBC results return after 6 months for repeat LBC testing. Those with abnormal (non-NILM) LBC

results are referred for colposcopy. If the colposcopy and histology results are abnormal, they receive

appropriate treatment, or if the results are normal, they return for a follow-up LBC in 12 months.

116 In the co-testing algorithm, all cervical samples have HR-HPV testing and LBC simultaneously (Figure 1).

117 Those with HR-HPV negative and normal LBC results return to the routine screening cycle (5 years).

118 Those with HR-HPV positive results and normal LBC results have a repeat co-test after 12 months and

119 those with repeat HR-HPV positive and/or LBC abnormal results are referred for colposcopy, whereas

120 those with negative results return to routine recall. At routine testing, those with abnormal LBC results

are referred for colposcopy immediately and if the biopsy is negative, return for an additional LBC after

122 6 months; those with normal LBC results return for repeat co-testing after 18 months.

Like the German co-testing algorithm, the co-testing algorithm includes a medium-risk group to simulate a more conservative follow-up of women who are HR-HPV negative and have borderline or low-grade LBC results. Instead of direct referral to colposcopy, a proportion of those with HR-HPV negative and abnormal but low-grade LBC baseline results receive follow-up LBC testing at 6 months (**Table 1**), and if LBC results are normal, return for repeat co-testing at 18 months. Those with abnormal LBC results are referred to colposcopy. The remainder are assumed to have higher grade LBC results and are directly referred to colposcopy. Patients exit the algorithm to return to routine recall after negative co-testing

7

- 130 results, after the second colposcopy with negative biopsy results, or after treatment after the biopsy. All
- 131 samples were assumed to give conclusive test results, with no inadequate samples.

132 Patient and public involvement

- 133 This is a theoretical analysis, using only published and routinely available data. No patients were
- involved at any stage of this study and only published aggregate patient data was used.

135 Outcomes

- 136 The primary outcomes of the study were total screening costs (from attendance at screening to
- 137 treatment for cervical intraepithelial neoplasia (CIN1-CIN3)), average cost per complete screen, cost per
- 138 CIN2+ and CIN3+ case, total number of colposcopies, number of HR-HPV and LBC tests performed, and
- 139 number of cervical precancer and cancer cases diagnosed.
- 140 The secondary outcomes were the total cost of colposcopies, total cost of HR-HPV and LBC tests, and
- 141 cost of treatment of CIN1, CIN2 and CIN3. The difference in costs and outcomes between the two
- screening algorithms were calculated (HR-HPV primary and co-testing).

143 <u>Population</u>

- 144 The simulated population represents 577,846 women in Belgium aged 25-64 attending screening in one
- 145 year, assuming a 5-year recall period. The most inclusive language for cervical screening is "women and
- people with a cervix" (Gov.uk, 2022); the term 'women' is used throughout this paper to reflect EU
- screening guidelines (European Commission, 2022) and Belgian literature (Arbyn Marc et al., 2015).

148 <u>Model parameters</u>

- 149 The model parameter inputs are detailed in **Table 1** and Error! Reference source not
- 150 found. Supplemental Table 1 and include screening coverage, probability of detecting HR-HPV and pre-

8

cancer (by age group), testing probabilities (HR-HPV primary, cytology, colposcopy), loss to follow up
and cost inputs.

153 Transition probability inputs

154 There is limited published individual patient-level data reporting long-term health outcomes associated

155 with different testing algorithms and no Belgian-specific data. The HORIZON study (Rebolj et al., 2016,

156 2015) (see **Supplemental Tables** for details), was conducted in Denmark and assessed 4,128 cervical

157 samples using four different HR-HPV assays and LBC, was selected as an appropriate source to inform

158 the clinical and diagnostic probability parameters.

159 The probability of detecting LBC abnormalities and abnormal colposcopy results (CIN1, CIN2 and CIN3)

160 or worse (Table 1) were calculated using data from the HORIZON study based on the results for cobas

161 4800 HR-HPV assay (Rebolj et al., 2016, 2015). Methods for calculating the transition probabilities for

162 primary HR-HPV testing are described in detail in a previous model (Weston et al., 2020). HORIZON

reported one case of cervical cancer in the study population. Due to the small sample size, this was

deemed not suitable for estimating cervical cancer in an entire screening population and therefore CIN3

or worse (CIN 3 and cervical cancer, CIN3+) was selected as the most appropriate outcome.

166 Screening coverage (62.6% baseline value) was informed using Flemish screening data (Flemish

167 Department of care, 2021).

168 Cost inputs

Costs in Belgium were estimated using published data (Annemans et al., 2008a; Fobelets et al., 2015a;
RIZIV, 2023a, 2023b, 2023c). All costs (presented in Euros) were inflated to 2023 values (Table 1) using
the IMF inflation index (CCEMG, 2022). The cost of all tests includes sampling and processing costs. The
cost of colposcopies and treatment were informed using published literature (Annemans et al., 2008b;
Fobelets et al., 2015b). The cost of the initial consultation was taken from RIZIV, a Belgian government

© Aquarius Population Health 2023

9

agency (RIZIV, 2023a). Costs incurred more than one year in the future were discounted by 3.0%, as

175 recommended by Belgian Healthcare Knowledge Centre (KCE) (Cleemput et al., 2012).

176 As test reimbursement remains uncertain and may vary in different programs and settings, a cost-

177 neutral pricing strategy was developed for co-testing in consultation with experts and is proposed as a

potential pricing approach for Belgium. The cost of LBC (€32.41) in the current LBC-based screening

algorithm which has a 3-year screening interval is equivalent to €10.80 per year. This yearly cost was

used to calculate a cost-neutral price for the co-testing package (HR-HPV and LBC) which has a 5-year

screening interval (i.e., €10.80 x 5 = €54.02). The discounting applied when HR-HPV testing and LBC are

used for all samples (co-testing) compared to when HR-HPV testing is used for all samples, but LBC is

used only for some (HR-HPV primary), is a commercial approach used in the past where two diagnostic

184 tests are used together.

185 Uncertainty analyses

186 *Deterministic sensitivity analyses*

187 Deterministic one-way sensitivity analyses (DSA) were conducted to assess the impact of changing each 188 parameter on the main outcomes. Low and high parameter values were individually varied to generate 189 results (Supplemental Table 2). The cost of colposcopy and treatment were varied by 20% to explore 190 potential future variations in costs. The co-testing package cost (co-testing algorithm) was varied by ≤ 20 ; 191 the cost of the HR-HPV test was varied by €20 and LBC by €10 in the HPV-primary algorithm. 192 Probabilities were varied based on the calculated standard error (SE). Those parameters with no SE 193 value assigned were varied by +/-25% of their baseline values. The low value for loss to follow-up was 194 assumed to be zero, indicating 100% compliance. Tornado plots are used to present the DSA for overall 195 costs, number of colposcopies, HR-HPV, LBC tests and cervical precancer and cancer diagnoses (Error! 196 **Reference source not found. Figure 1**). Parameters that impacted the results by $\geq 10\%$ are reported.

10

197 Probabilistic sensitivity analysis

198	Probabilistic sensitivity analysis (PSA) was performed to explore the robustness of results by running the
199	model 1,000 times independently using a Monte Carlo simulation. All input cost parameters were
200	assigned a Gamma distribution, and beta distribution was used for probability inputs from 0 to 1, which
201	were calculated based on estimated alpha and beta values (Supplemental Table 2, Supplemental Table
202	3). The same values were used for parameters used in both co-testing and HR-HPV primary algorithms
203	(e.g., probability of loss to follow-up for colposcopy). The 95% confidence intervals (CI) were calculated
204	from the results of 1,000 iterations.
205	Scenario analyses

In the first two scenario analyses, an increased HR-HPV vaccination coverage was assumed (compared to
0% in the base case) for women <30 years to simulate HPV vaccinated women entering the screening
cohort. The reduced probability of an HR-HPV positive test was calculated using relative risk data from
published studies (Supplemental Table 4). Scenario 1 represented current vaccination coverage: 67%
(Bruni et al., 2023), and Scenario 2, the target coverage: 90% (WHO, 2020b). In Scenario 3, the current
reimbursement cost for the HR-HPV test (€67.90) (RIZIV, 2023c) and the LBC cost (€32.41) was used in
both screening algorithms.

213 Results

214 Baseline results

The primary outcomes are presented in **Table 2**. Using the cost-neutral pricing strategy for co-testing, implementing co-testing, which has a different follow-up algorithm (**Figure 1**), would save an average of €11.80 per person screened compared to the HR-HPV primary algorithm. The co-testing algorithm would require an additional 13,173 colposcopies, 67,731 HR-HPV tests and 477,020 LBC tests for the screening cohort (the total programme costs of €58.8M for co-testing and €65.6M for HR-HPV primary in **Table 2**).

However, co-testing, would detect an additional 2,351 CIN2+ cases (Figure 2), of which 1,602 would be

221	CIN3+ cases, representing an increase of 27.4% and 24.3% respectively. The average cost per CIN2+ case
222	detected was €5,381 for co-testing compared to €7,650 for HR-HPV primary (Table 4). Cost outcomes
223	are presented in Table 3. The cost of HR-HPV testing contributed the largest component of the total cost
224	in both screening algorithms (81% of total costs in HR-HPV primary and 56% for co-testing) (Table 3).
225	The cost of LBC was the second largest contributor to overall costs.
226	Deterministic sensitivity analysis (DSA)
227	The impact of varying each input value between its low and high value are presented in Supplemental
228	Figure 1. The unit cost of consultation, and of HR-HPV testing and LBC are the main drivers influencing
229	the total cost for both algorithms. Screening coverage was an important driver of the total cost, the total
230	number of colposcopies, LBC, and HR-HPV tests. The probability of CIN3 at 18 months, given a positive
231	HR-HPV test in the HR-HPV primary algorithm or positive results in both tests in the co-testing algorithm
232	at baseline, has an impact on the total number of CIN2+ and CIN3+ cases in both algorithms.
233	Probabilistic sensitivity analysis (PSA)
234	The results of the PSA are shown in Supplemental Figure 2 . Implementation of the co-testing algorithm
235	led to a greater number of HR-HPV tests, LBC and colposcopies in all iterations compared to the HR-HPV
236	primary algorithm, with a lower total cost in 82.8% of 1,000 iterations. The co-testing algorithm
237	detected more CIN2+ cases in 92.7% and more CIN3+ cases in 87.6% of 1,000 iterations.
238	<u>Scenario analysis</u>
239	Scenario 1 and 2 simulated vaccination coverage of 67% (46,671) and 90% (62,693) of women under 30
240	(69,659). These changes resulted in a decrease in total costs of 1.4% and 1.9% for HR-HPV primary and
241	1.6% and 2.2% for co-testing algorithm, respectively, due to fewer positive HR-HPV tests at baseline.

12

242	Scenario 3 increased the total cost by 51% compared to using the cost-neutral pricing strategy for co-
243	testing pathway. Total costs for the co-testing pathway were €88.6M compared to the HR-HPV primary
244	pathway total costs of €65.6M. The full results of all scenario analyses are presented in Supplemental
245	Table 7
246	Discussion
247	<u>Main findings</u>
248	This modelling study compares two hypothetical algorithms for cervical cancer screening in Belgium. The
249	results indicate that, using the algorithms modelled here, co-testing would detect more cervical
250	precancer and reduce the risks of missing cases and potentially save costs when using a cost-neutral
251	approach for pricing the co-testing package. This comes at an increased use of healthcare resources due
252	to the additional diagnostic tests performed. Uncertainty analyses show that the total costs of both
253	algorithms are sensitive to the reimbursement of HR-HPV and LBC tests. Notably, when applying the
254	same reimbursement rates for these tests, the co-testing algorithm becomes more costly compared to
255	the HR-HPV algorithm. These results can provide useful evidence to help inform decisions on shaping an
256	optimal screening strategy in Belgium.
257	Strengths & Limitations
258	While previous economic modelling studies have compared LBC primary and HR-HPV primary screening

259 (Mendes et al., 2015), research comparing co-testing to HPV primary is limited. This is the first study to

260 compare co-testing to HR-HPV primary testing in cervical screening in Belgium. The model was adapted

from previously published cervical screening models (Dombrowski et al., 2022; Weston et al., 2021,

262 2020), and adapted to the healthcare system in Belgium.

13

263	Results from this study align with surveillance data from Germany (co-testing screening) and the
264	Netherlands (HPV primary screening) which provides validation of the model structure and inputs. In the
265	co-testing algorithm, 4.9% of the screening population have colposcopies with 0.5% resulting in the
266	detection of CIN2+ similar to a German co-testing surveillance study reporting approximately 3%
267	ASCUS/AGC or worse results (referral to colposcopy) and 0.5% HSIL or worse (corresponding to CIN2+) in
268	2021 (Xhaja et al., 2022). In the HR-HPV primary algorithm, 2.6% of the screening population have
269	colposcopies with 1.5% resulting in detection of CIN2+. Likewise in 2021, 2.6% of the screening
270	population in the Netherlands underwent colposcopies and CIN2+ was detected in 1.1% (RIVM, 2021).
271	As with any model, assumptions were made regarding the model structure and inputs. As Belgium does
272	not currently use a co-testing clinical algorithm, a hypothetical co-testing algorithm was adapted from
273	co-testing algorithms in Germany and Luxembourg. There were no data on primary HR-HPV screening or
274	co-testing for Belgium, so data from other trials were used (Rebolj et al., 2016, 2015). This has been
275	deemed an appropriate approach for other studies in the absence of applicable data (EUnetHTA, 2015).
276	Since the model uses HORIZON results for the cobas 4800 HR-HPV assay, it simulates the use of this
277	assay, however, the choice of HR-HPV assay used may impact the outcomes, as different assays have
278	different sensitivity and specificity. The reimbursement for tests may change in the implementation of
279	the national programme in Belgium. Sensitivity analyses found the reimbursement of HPV and LBC tests
280	to be key factors in the total cost and cost per precancer detected. However, the impact of varying these
281	values were assessed in uncertainty analyses and indicated that the main conclusions would not change,
282	lending support for the validity of the modelling work.
283	The follow-up periods in the algorithms derived from real-world screening algorithms used in
284	neighbouring countries contribute to the difference in number of CIN2+ and CIN3+ detected between

the two alternative screening algorithms (shown in **Supplemental Table 5**). The underlying assumption

14

- is the probability of detection of cytological abnormalities increases over time, which may overestimate
- the difference of CIN2+ numbers between two algorithms.
- 288 While considering the long-term costs of cancer treatment (co-testing and HR-HPV primary) suggests
- that co-testing offers improved health and economic outcomes (Felix et al., 2016), the model evaluated
- 290 the short-term impact of one round of screening including routine screen and follow up and did not
- include the complexity of disease progression and repeated screening over a lifetime. Taking a simpler
- approach yields a conservative estimate of the benefits as the true benefits of implementing cervical
- 293 screening may be underestimated.
- 294 Future work
- 295 While it is not necessary to perform a study in Belgium ahead of making decisions to implement a
- 296 national screening programme, after implementation, the surveillance data from Belgium could be used
- to validate the results of this study. Moreover, the difference between theoretical and empirical results
- 298 could be compared, and the model results refined.
- 299 Studies in Belgium have found lower rates of HR-HPV infections and cervical abnormalities in the
- vaccinated population (Arbyn et al., 2016). An increasingly vaccinated population entering the cervical
- 301 screening programme is likely to have a considerable impact due to an overall reduction in HR-HPV
- 302 prevalence (Lei et al., 2020), but also a strong relative increase of HPV-negative lesions, and a small
- 303 absolute increase (Falcaro et al., 2021).

Additional modelling including disease progression, and consideration of new methods to improve cancer detection such as genotype profiling, DNA methylation, artificial intelligence, will be useful in evaluating the optimal screening algorithm and may trigger changing the screening interval or the testing approach (Bedell et al., 2020; Simms et al., 2017).

308 <u>Conclusion</u>

- 309 These findings support a co-testing cervical screening algorithm in Belgium if the aim is to maximise the
- number of women with abnormalities found, minimise the risk of missing cases, and minimise the total
- 311 cost (compared to a HR-HPV strategy) if a cost-neutral discounted co-testing package price was used.
- 312 The improved detection of pre-cancerous lesions ensures women receive treatment at the earliest
- 313 opportunity, reducing more severe treatments and mortality.

References

314 Annemans, L., Rémy, V., Lamure, E., Spaepen, E., Lamotte, M., Muchada, J.-P., Largeron, N., 2008a. 315 Economic burden associated with the management of cervical cancer, cervical dysplasia and 316 genital warts in Belgium. J. Med. Econ. 11, 135–150. 317 https://doi.org/10.3111/13696990801961611 318 Annemans, L., Rémy, V., Lamure, E., Spaepen, E., Lamotte, M., Muchada, J.-P., Largeron, N., 2008b. 319 Economic burden associated with the management of cervical cancer, cervical dysplasia and 320 genital warts in Belgium. Med Econ 11, 135–150. https://doi.org/10.3111/13696990801961611 321 Anttila, A., Ronco, G., Clifford, G., Bray, F., Hakama, M., Arbyn, M., Weiderpass, E., 2004. Cervical cancer 322 screening programmes and policies in 18 European countries. Br. J. Cancer 91, 935–941. 323 https://doi.org/10.1038/sj.bjc.6602069 324 Arbyn, M., Broeck, D.V., Benoy, I., Bogers, J., Depuydt, C., Praet, M., Sutter, P.D., Hoorens, A., Hauben, 325 E., Poppe, W., Ranst, M.V., Delvenne, P., Gofflot, S., Pétein, M., Engelen, F., Vanneste, A., Beeck, L.O.D., Damme, P.V., Temmerman, M., Weyers, S., 2016. Surveillance of effects of HPV 326 327 vaccination in Belgium. Cancer Epidemiol. 41, 152–158. 328 https://doi.org/10.1016/j.canep.2015.12.011 329 Arbyn, M., Fabri, V., Temmerman, M., Simoens, C., 2014. Attendance at Cervical Cancer Screening and 330 Use of Diagnostic and Therapeutic Procedures on the Uterine Cervix Assessed from Individual 331 Health Insurance Data (Belgium, 2002-2006). PLOS ONE 9, e92615. 332 https://doi.org/10.1371/journal.pone.0092615 333 Arbyn Marc, Haelens Annemie, Desomer Anja, Verdoodt Freija, Francart Julie, Thiry Nancy, Hanquet 334 Germaine, 2015. Quel dépistage pour le cancer du col? (Health Technology Assessment (HTA) 335 No. KCE Reports 238B). Centre Fédéral d'Expertise des Soins de Santé (KCE), Bruxelles. 336 Austin R.M., Onisko A., Zhao C., 2018. Enhanced detection of cervical cancer and precancer through use 337 of imaged liquid-based cytology in routine cytology and HPV cotesting. Am. J. Clin. Pathol. 150, 338 385–392. https://doi.org/10.1093/ajcp/aqy114 339 Bedell, S.L., Goldstein, L.S., Goldstein, A.R., Goldstein, A.T., 2020. Cervical Cancer Screening: Past, 340 Present, and Future. Sex. Med. Rev. 8, 28–37. https://doi.org/10.1016/j.sxmr.2019.09.005 341 Blatt, A.J., Kennedy, R., Luff, R.D., Austin, R.M., Rabin, D.S., 2015a. Comparison of cervical cancer 342 screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 123, 343 282-288. https://doi.org/10.1002/cncy.21544 344 Blatt, A.J., Kennedy, R., Luff, R.D., Austin, R.M., Rabin, D.S., 2015b. Comparison of cervical cancer 345 screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 123, 346 282-288. https://doi.org/10.1002/cncy.21544 347 Bonanni, P., Faivre, P., Lopalco, P.L., Joura, E.A., Bergroth, T., Varga, S., Gemayel, N., Drury, R., 2020. The 348 status of human papillomavirus vaccination recommendation, funding, and coverage in WHO 349 Europe countries (2018–2019). Expert Rev. Vaccines 19, 1073–1083. 350 https://doi.org/10.1080/14760584.2020.1858057 351 Bruni, L., Albero, G., Serrano, B., Mena, M., Collado, J., Gomez, D., Munoz, J., Bosch, F., de Sanjose, S., 352 2023. Human Papillomavirus and Related Diseases in Belgium. Summary Report. ICO/IARC 353 Information Centre on HPV and Cancer (HPV Information Centre). 354 CCEMG, 2022. EPPI-Centre Cost Converter v.1.4 [WWW Document]. URL 355 https://eppi.ioe.ac.uk/costconversion/default.aspx (accessed 10.21.22). 356 Cleemput, I., Neyt, M., Van de Sande, S., Thiry, N., 2012. Belgian guidelines for economic evaluations and 357 budget impact analyses, 2nd ed, KCE Reports. Belgian Health Care Knowledge Centre (KCE), BE.

358	Depuydt, C.E., Leuridan, E., Van Damme, P., Bogers, J., Vereecken, A.J., Donders, G.G.G., 2010.
359	Epidemiology of Trichomonas vaginalis and human papillomavirus infection detected by real-
360	time PCR in flanders. Gynecol. Obstet. Invest. 70, 273–280. https://doi.org/10.1159/000314017
361	Dombrowski, C.A., Weston, G.M., Descamps, P.P., Izopet, P.J., Adams, E.J., Adams, E., 2022. Health
362	economic evaluation of an mRNA high-risk human papillomavirus (HR-HPV) assay versus a DNA
363	HR-HPV assay for the proposed French cervical screening programme. Medicine (Baltimore)
364	101, e29530. https://doi.org/10.1097/MD.000000000029530
365	EUnetHTA, 2015. Methods for health economic evaluations - A guideline based on current practices in
366	Europe.
367	European Commission, 2022. European Health Union: cancer screening [WWW Document]. Eur. Comm.
368	- Eur. Comm. URL https://ec.europa.eu/commission/presscorner/detail/en/ip_22_5562
369	(accessed 11.30.22).
370	Falcaro, M., Castañon, A., Ndlela, B., Checchi, M., Soldan, K., Lopez-Bernal, J., Elliss-Brookes, L., Sasieni,
371	P., 2021. The effects of the national HPV vaccination programme in England, UK, on cervical
372	cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational
373	study. Lancet Lond. Engl. 398, 2084–2092. https://doi.org/10.1016/S0140-6736(21)02178-4
374	Felix, J.C., Lacey, M.J., Miller, J.D., Lenhart, G.M., Spitzer, M., Kulkarni, R., 2016. The Clinical and
375	Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A
376	Modeling Analysis. J. Womens Health 25, 606–616. https://doi.org/10.1089/jwh.2015.5708
377	Flemish Department of care, 2021. Annual Report on Cancer Population Screening 2021 [WWW
378	Document]. URL https://www.zorg-en-gezondheid.be/nieuws/jaarrapport-
379	bevolkingsonderzoeken-naar-kanker-2021 (accessed 6.13.23).
380	Fobelets, M., Pil, L., Putman, K., Annemans, L., 2015a. De kosteneffectiviteit van het
381	bevolkingsonderzoek naar baarmoederhalskanker in Vlaanderen: gezondheidseconomische
382	evaluatie 38.
383	Fobelets, M., Pil, L., Putman, K., Annemans, L., 2015b. De kosteneffectiviteit van het
384	bevolkingsonderzoek naar baarmoederhalskanker in Vlaanderen: gezondheidseconomische
385	evaluatie 38.
386	Fontham, E.T.H., Wolf, A.M.D., Church, T.R., Etzioni, R., Flowers, C.R., Herzig, A., Guerra, C.E., Oeffinger,
387	K.C., Shih, YC.T., Walter, L.C., Kim, J.J., Andrews, K.S., DeSantis, C.E., Fedewa, S.A.,
388	Manassaram-Baptiste, D., Saslow, D., Wender, R.C., Smith, R.A., 2020. Cervical cancer screening
389	for individuals at average risk: 2020 guideline update from the American Cancer Society. CA.
390	Cancer J. Clin. 70, 321–346. https://doi.org/10.3322/caac.21628
391	Gov.uk, 2022. Cervical screening: helping you decide [WWW Document]. GOV.UK. URL
392	https://www.gov.uk/government/publications/cervical-screening-description-in-brief/cervical-
393	screening-helping-you-decide2 (accessed 11.23.22).
394	Iftner, T., 2021. What is the situation on cervical cancer screening in Germany as an European example?
395	Jansen, E.E.L., Zielonke, N., Gini, A., Anttila, A., Segnan, N., Vokó, Z., Ivanuš, U., McKee, M., de Koning,
396	H.J., de Kok, I.M.C.M., Veerus, P., Anttila, A., Heinävaara, S., Sarkeala, T., Csanádi, M., Pitter, J.,
397	Széles, G., Vokó, Z., Minozzi, S., Segnan, N., Senore, C., van Ballegooijen, M., Driesprong - de Kok,
398	I., Gini, A., Heijnsdijk, E., Jansen, E., de Koning, H., Lansdorp – Vogelaar, I., van Ravesteyn, N.,
399	Zielonke, N., Ivanus, U., Jarm, K., Mlakar, D.N., Primic-Žakelj, M., McKee, M., Priaulx, J., 2020.
400	Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic
401	review. Eur. J. Cancer 127, 207–223. https://doi.org/10.1016/j.ejca.2019.12.013
402	Kaufman, H.W., Alagia, D.P., Chen, Z., Onisko, A., Austin, R.M., 2020. Contributions of Liquid-Based
403	(Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical
404	Cancer and Precancer in the United States. Am. J. Clin. Pathol. 154, 510–516.
405	https://doi.org/10.1093/ajcp/aqaa074
	, , , , , , , , , , , , , , , , , , ,

406	Lei, J., Ploner, A., Lehtinen, M., Sparén, P., Dillner, J., Elfström, K.M., 2020. Impact of HPV vaccination on
407	cervical screening performance: a population-based cohort study. Br. J. Cancer 123, 155–160.
408	https://doi.org/10.1038/s41416-020-0850-6
409	Maver, P.J., Poljak, M., 2020. Primary HPV-based cervical cancer screening in Europe: implementation
410	status, challenges, and future plans. Clin. Microbiol. Infect. 26, 579–583.
411	https://doi.org/10.1016/j.cmi.2019.09.006
412	Mendes, D., Bains, I., Vanni, T., Jit, M., 2015. Systematic review of model-based cervical screening
413	evaluations. BMC Cancer 15, 334. https://doi.org/10.1186/s12885-015-1332-8
414	Monsonego, J., Bosch, F.X., Coursaget, P., Cox, J.T., Franco, E., Frazer, I., Sankaranarayanan, R., Schiller,
415	J., Singer, A., Wright, T., Kinney, W., Meijer, C., Linder, J., 2004. Cervical cancer control, priorities
416	and new directions. Int. J. Cancer 108, 329–333. https://doi.org/10.1002/ijc.11530
417	Rebolj, M., Bonde, J., Ejegod, D., Preisler, S., Rygaard, C., Lynge, E., 2015. A daunting challenge: Human
418	Papillomavirus assays and cytology in primary cervical screening of women below age 30years.
419	Eur. J. Cancer 51, 1456–1466. https://doi.org/10.1016/j.ejca.2015.04.012
420	Rebolj, M., Bonde, J., Preisler, S., Ejegod, D., Rygaard, C., Lynge, E., 2016. Human Papillomavirus Assays
421	and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above. PLOS ONE 11,
422	e0147326. https://doi.org/10.1371/journal.pone.0147326
423	Rebolj, M., Cuschieri, K., Mathews, C.S., Pesola, F., Denton, K., Kitchener, H., 2022. Extension of cervical
424	screening intervals with primary human papillomavirus testing: observational study of English
425	screening pilot data. BMJ 377, e068776. https://doi.org/10.1136/bmj-2021-068776
426	RIVM, 2021. Monitorbevolkingsonderzoek baarmoederhalskanker 2021 [WWW Document]. URL
427	https://www.rivm.nl/documenten/monitor-bevolkingsonderzoek-baarmoederhalskanker-2021
428	(accessed 5.6.22).
429	RIZIV, 2023a. Honoraria, prijzen en vergoedingen [WWW Document]. URL
430	https://www.riziv.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/individuele-
431	verzorging/honoraires/Paginas/default.aspx#:~:text=Het%20verschil%20tussen%20de%20honor
432	aria,een%20overeenkomst%20of%20een%20akkoord. (accessed 10.31.22).
433	RIZIV, 2023b. Nomensoft: Nomenclatuur en pseudonomenclatuur van de geneeskundige verstrekkingen
434	- 589864 [WWW Document]. Honor. En Vergoedingen Tegemoetkomingen Van Verzek. URL
435	https://webappsa.riziv-inami.fgov.be/Nomen/nl/589864/fees (accessed 5.23.23).
436	RIZIV, 2023c. Nomensoft: Nomenclatuur en pseudonomenclatuur van de geneeskundige verstrekkingen
437	- 588932 [WWW Document]. Honor. En Vergoedingen Tegemoetkomingen Van Verzek. URL
438	https://webappsa.riziv-inami.fgov.be/Nomen/nl/588932/fees (accessed 7.14.23).
439	RIZIV, 2023d. Raadpleging in de spreekkamer door een arts-specialist in de neurologie, inclusief een
440	eventueel schriftelijk.
441	Ronco, G., Dillner, J., Elfström, K.M., Tunesi, S., Snijders, P.J.F., Arbyn, M., Kitchener, H., Segnan, N.,
442	Gilham, C., Giorgi-Rossi, P., Berkhof, J., Peto, J., Meijer, C.J.L.M., 2014. Efficacy of HPV-based
443	screening for prevention of invasive cervical cancer: follow-up of four European randomised
444	controlled trials. The Lancet 383, 524–532. https://doi.org/10.1016/S0140-6736(13)62218-7
445	Secrétariat du Conseil Scientifique, 2019. Dépistage du cancer du col de l'utérus - version longue (2019).
446	Simms, K.T., Hall, M., Smith, M.A., Lew, JB., Hughes, S., Yuill, S., Hammond, I., Saville, M., Canfell, K.,
447	2017. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-
448	Effectiveness Evaluation for the National Cervical Screening Program in Australia. PloS One 12,
449	e0163509. https://doi.org/10.1371/journal.pone.0163509
450	STATBEL, 2022. Population by place of residence, nationality (Belgian/non-Belgian), marital status, age
451	and gender [WWW Document]. URL
452	https://bestat.statbel.fgov.be/bestat/crosstable.xhtml?datasource=65ee413b-3859-4c6f-a847-
453	09b631766fa7 (accessed 5.6.22).

454 455 456 457 458 459 460 461 462 463 464 465 466	 Thiry, N., Gerkens, S., Cornelis, J., Jespers, V., Hanquet, G., 2019. Cost-effectiveness analysis of HPV vaccination of boys in Belgium, KCE Reports. Belgian Health Care Knowledge Centre (KCE), BE. Van Kerrebroeck, H., Makar, A., 2016. Cervical cancer screening in Belgium and overscreening of adolescents. Eur. J. Cancer Prev. 25, 142–148. https://doi.org/10.1097/CEJ.00000000000000155 Vasilyeva, D., Tiscornia-Wasserman, P., Gonzalez, A.A., 2021. Negative Roche cobas HPV testing in cases of biopsy-proven invasive cervical carcinoma, compared with Hybrid Capture 2 and liquid-based cytology. J. Am. Soc. Cytopathol. 10, 128–134. https://doi.org/10.1016/j.jasc.2020.08.006 Weston, G., Dombrowski, C., Harvey, M.J., Iftner, T., Kyrgiou, M., Founta, C., Adams, E.J., 2020. Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation. BMJ Open 10, e031303. https://doi.org/10.1136/bmjopen-2019-031303 Weston, G., Dombrowski, C., Steben, M., Popadiuk, C., Bentley, J., Adams, E.J., 2021. A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a
467 468	hypothetical HPV primary screening algorithm in Ontario, Canada. Prev. Med. Rep. 23, 101448. https://doi.org/10.1016/j.pmedr.2021.101448
469	WHO, 2022. Cervical cancer - Key facts [WWW Document]. Cerv. Cancer. URL
470	https://www.who.int/news-room/fact-sheets/detail/cervical-cancer (accessed 5.30.23).
471	WHO, 2020a. Global strategy to accelerate the elimination of cervical cancer as a public health problem.
472	WHO, 2020b. Global strategy to accelerate the elimination of cervical cancer as a public health problem
473	[WWW Document]. URL https://www.who.int/publications-detail-redirect/9789240014107
474	(accessed 11.8.22).
475	Xhaja, A., Ahr, A., Zeiser, I., Ikenberg, H., 2022. Two Years of Cytology and HPV Co-Testing in Germany:
476	Initial Experience. Geburtshilfe Frauenheilkd. https://doi.org/10.1055/a-1886-3311
477	Zorg en Gezondheid, 2021. Jaarrapport bevolkingsonderzoeken naar kanker 2021 [WWW Document].
478	URL https://www.zorg-en-gezondheid.be/nieuws/jaarrapport-bevolkingsonderzoeken-naar-
479	kanker-2021 (accessed 11.10.22).

Table 1. Key model input parameters baseline values

	Age	Screening	Baseline	Reference		
De une e une a bie	group	Algorithm	value			
Demographic		1		·		
Screening coverage	Both	Both	62.6%	(Zorg en Gezondheid, 2021)		
Total women attending cervical screening	Both	Both	577,846	(STATBEL, 2022; Zorg en Gezondheid, 2021)		
Women aged 25-29	<30	Both	69,659			
- Women aged 30-64	≥30	Both	508,187	-		
Time to recall for a control cytology following a positive co-test at baseline (months)	Both	Co-testing	6	(Iftner, 2021)		
Time to recall for a repeat co-test following a positive co-test at baseline (months)	Both	Co-testing	12			
Time to recall for a colposcopy following a positive co-test at baseline (months)	Both	Co-testing	1			
% of HR-HPV negative & LBC positive defined as medium risk at baseline	Both	Co-testing	0.74 ¹	(Rebolj et al., 2016, 2015)		
% of colposcopies with biopsy for women who underwent colposcopies	Both	Both	0.0700	(Rebolj et al., 2022)		
Loss to follow-up for LBC and co- testing for women who had abnormal screening results	Both	Both	0.3130	(Zorg en Gezondheid, 2021)		
Loss to follow-up for colposcopy for women who had abnormal screening results	Both	Both	0.3130	(Blatt et al., 2015b)		
Testing and treatment costs (all value	s in €)					
HR-HPV test	Both	HR-HPV primary	67.90	(RIZIV, 2023b)		
LBC test		HR-HPV primary	32.41	(RIZIV, 2023c)		
AHR-HPV test plus LBC test	Both	Co-testing ²	54.02 ²	Expert opinion		
Follow-up LBC test	Both	Co-testing	32.41	(RIZIV, 2023c)		
Colposcopy with biopsy	Both	Both	91.40	(Fobelets et al.,		
Colposcopy without biopsy	Both	Both	34.31	2015b)		
Cost of consultation in which a swab is taken	Both	Both	23.83	(RIZIV, 2023d)		
CIN 1 treatment	Both	Both	284.28	(Annemans et al.,		
CIN 2 treatment	Both	Both	378.47	2008b)		
CIN 3 treatment	Both	Both	488.32	,		
Cervical cancer treatment	Both	Both	5,117.43			
Cost annual discount rate	Both	Both	3.0%	(Cleemput et al., 2012)		

21

	Age	Screening	Baseline	Reference			
	group	Algorithm	value				
Clinical and diagnostic probabilities							
Positive HR-HPV test at baseline for	<30	HR-HPV primary	0.4061	(CCEMG, 2022;			
all screened women	≥30	HR-HPV primary	0.1621	Fobelets et al., 2015a)			
Negative HR-HPV test & negative LBC test at baseline for all	<30	Co-testing	0.5876	(Cleemput et al., 2012)			
screened women	≥30	Co-testing	0.8212				
Negative HR-HPV test & positive LBC test at baseline for all	<30	Co-testing	0.7400	(Rebolj et al., 2016, 2015)			
screened women	≥30	Co-testing	0.0043				
Positive HR-HPV test & negative LBC test at baseline (medium risk)	<30	Co-testing	0.0046	Assumption			
LDC test at baseline (medium risk)	≥30	Co-testing	0.0124	-			
Positive HR-HPV test & negative LBC test at baseline for all	<30	Co-testing	0.3380	(Rebolj et al., 2016,			
screened women	≥30	Co-testing	0.1345	. 2015)			
Positive HR-HPV test & positive LBC test at baseline for all screened	<30	Co-testing	0.0681				
women	≥30	Co-testing	0.0275				
CIN 1 at baseline if HR-HPV positive	<30	HR-HPV primary	0.1964				
at baseline for all screened women	≥30	HR-HPV primary	0.1724				
CIN 2 at baseline if HR-HPV positive	<30	HR-HPV primary	0.1429				
at baseline for all screened women	≥30	HR-HPV primary	0.1379				
CIN 3 at baseline if HR-HPV positive	<30	HR-HPV primary	0.4464				
at baseline for all screened women	≥30	HR-HPV primary	0.5000				
Cervical cancer at baseline if HR-	<30	HR-HPV primary	0 ³				
HPV positive at baseline for all screened women	≥30	HR-HPV primary	0 ³				

Abbreviations: CIN, Cervical squamous intraepithelial neoplasia; DSA, Deterministic sensitivity analysis; LBC, Liquid-based cytology; HR-HPV, High-risk human papillomavirus.

¹Total low grade LBC results (74% of all with baseline HR-HPV negative and LBC abnormal results) were calculated from the LBC results ((a typical squamous cells of undetermined significance (ASCUS) (48%) and low-grade squamous intraepithelial lesions (LSIL) (26%)) of those with and baseline HR-HPV negative results in the HORIZON data.

²The cost of a co-testing package (HR-HPV and LBC test) performed at a screening interval of 5 years, €54.02, was calculated from the annual cost of an LBC test at a screening interval of 3 years of €32.41.

³ No cases of cervical cancer were reported in the HORIZON study for those with positive cobas HR-HPV tests at baseline.

Only key probability input parameters which have larger impact on primary results have been presented in this table; a complete list of input parameters is presented in Error! Reference source not found..

480

23

Table 2. Primary outcomes under baseline assumptions for HR-HPV primary and co-testing algorithms

for cervical screening (cohort N=577,846)

Screening Algorithm	Total programme cost (€)	Cost per screen (€)	Number of colposcopies	HR-HPV tests	LBC tests	CIN2+ diagnoses	CIN3+ diagnoses
Co-testing	58,775,083	101.7	28,055	645,577	652,555	10,924	8,199
HR-HPV primary	65,588,573	113.5	14,882	577,846	175,535	8,573	6,597

Abbreviations: CIN, Cervical squamous intraepithelial neoplasia; HR-HPV, Human papillomavirus.

Table 3. Secondary outcomes under baseline assumptions for HR-HPV primary and co-testingalgorithms for cervical screening (cohort N=577,846).

Screening Algorithm	Colposcopies (€)	HR-HPV tests (€)	LBC tests (€)	CIN 1 treatment (€)	CIN 2 treatment (€)	CIN 3+ treatment (€)
Co-testing	1,071,664	32,811,275	17,825,880	1,510,269	1,030,170	4,525,826
HR-HPV primary	569,078	53,005,826	7,233,726	810,690	747,902	3,221,352

Abbreviations: CIN – Cervical squamous intraepithelial neoplasia; HR-HPV – Human papillomavirus. CIN 3+ includes cost of treatment of CIN 3 and cervical cancer.

Table 4. Average cost (€) and number of colposcopies per CIN 2+ and CIN 3+ case for HR-HPV primary and co-testing algorithms for cervical screening

Screening Algorithm	Average cost per CIN2+ case (€)	Average cost per CIN3+ case (€)	Average number of colposcopies per CIN2+ case
Co-testing	€5,381	€7,169	2.6
HR-HPV primary	€7,650	€9,942	1.7

Abbreviations: CIN – Cervical squamous intraepithelial neoplasia; HR-HPV – Human papillomavirus.




Figure 1. HR-HPV primary and co-testing screening pathways




Figure 1. Number of CIN2 and CIN3+ cases diagnosed by screening algorithm